Shots:

• The P-I (TROPION-PanTumor01) trial evaluating the safety & preliminary efficacy of datopotamab deruxtecan in 770 patients with advanced solid tumors that have relapsed or are refractory to standard treatment
• The results showed an encouraging & durable efficacy, ORR (27%) as assessed by BICR, all responses were partial & 56% achieved SD, DCR (85%), m-PFS was 8.3mos., m-DoR & m-OS had not been reached with a median follow-up of 13.7mos. & 59% were alive for ≥1yr.
• The safety profile was consistent with prior data with no new safety signals identified, AEs leading to treatment discontinuations were reported in 12% of patients & no cases of grade ≥3 diarrhea or febrile neutropenia were observed

Ref: Businesswire | Image: Daiichi Sankyo